Considering the same scenario, Gafita et al. proposed a PSMA-PET response evaluation criteria for metastatic castration-resistant PCa (mCRPCa) patients treated with [177Lu]Lu-PSMA therapy, termed RECIP. This evidence concerns the gene FOLH1 and posterior cortical atrophy.